Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is structurally distinct from other benzodiazepines and has a longer elimination half-life.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Initial Dose:** 5 mg twice daily.
* **Maintenance Dose:** Titrate dose upwards by 5-10 mg/day every week based on clinical response and tolerability.
* **Usual Maintenance Dose:** 10 mg to 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2 to <10 years or <30 kg)
* **Initial Dose:** 2.5 mg twice daily.
* **Maintenance Dose:** Titrate dose upwards by 2.5-5 mg/day every week based on clinical response and tolerability.
* **Usual Maintenance Dose:** 5 mg twice daily.
* **Maximum Dose:** 10 mg twice daily (20 mg/day).
*Note: Dosing for pediatric patients 10 years or older and weighing at least 30 kg should follow adult dosing guidelines.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be appropriate due to potential for increased sedation.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established.
## Contraindications
* Known hypersensitivity to clobazam or any other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, lethargy, aggression, irritability, upper respiratory tract infection, vomiting, ataxia, pneumonia.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior and ideation, withdrawal symptoms (including rebound seizures), respiratory depression.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and potentially fatal outcomes. Use concomitantly with extreme caution, and consider dose reduction of one or both agents.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam plasma concentrations. Monitor for increased adverse effects.
* **CYP2C19 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam plasma concentrations. Monitor for reduced efficacy.
* **Phenobarbital and primidone:** Clobazam may increase the serum concentrations of phenobarbital and primidone. Monitor for toxicity.
## Monitoring
* Monitor for therapeutic efficacy and adverse effects, particularly somnolence, ataxia, and behavioral changes.
* Monitor for signs of respiratory depression, especially when used with other CNS depressants.
* Monitor for suicidal behavior and ideation.
* Monitor for signs and symptoms of severe rash.
* Advise patients on potential for withdrawal symptoms upon discontinuation.
## Clinical Pearls
* Clobazam is generally used as an adjunctive therapy for specific seizure types like Lennox-Gastaut syndrome.
* Due to its long half-life, accumulation can occur, especially with higher doses or in patients with impaired hepatic function.
* Abrupt discontinuation can lead to withdrawal symptoms, including seizures. Tapering of the dose is recommended.
* The risk of severe skin reactions, although rare, necessitates immediate discontinuation of clobazam if suspected.
* Clobazam can be crushed and mixed with a small amount of liquid or soft food for administration.
---
***Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and current guidelines for complete details before making any treatment decisions. Dosing and recommendations may vary based on individual patient factors and local protocols.*
